Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow

• First Year Infection Risk in SLE Patients Treated with Rituximab versus Standar…

#ACR21 #Abstr1462 More case against Low dose Hydroxychloroquine as could ⬆️ risk of #lupus flares. Adjusted risk as below: Weight =>80kg, <400mg/d dose (OR 8.3) Weight <80kg, <300mg/d dose (OR 2.6) @RheumNow https://t.co/bTRMJDoSoI https://t.co/yzopiO3Kbo

• Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares - A…

Alcohol and MTX don't go along! In a cohort of 1000+ early RA Factors associated w/ 1️⃣Nausea Female OR 2 🍺 Alcohol OR 1.44 DAS28CRP OR 1.16 2️⃣Alopecia Age OR 4.87 🍺 Alcohol OR 1.98 HAQ score OR 1.62 #Abst1444 #ACR21 @RheumNow https://t.co/zZG6aFR1SX

👉HCQ dose < 400 mg/d are assc with SLE flare. Lower doses of HCQ may decrease risk of retinopathy. 👉For >80 kg (176 lbs), any dose < 400 mg/day is assc with increased odds of flare (HCQ blood levels not measured) Abst#1462 #ACR21 @rheumnow https://t.co/5tx3kruT8W

@ericdeinmd Although the MTX/alopecia - nausea poster was interesting. Abst#1444 #ACR21 Factors assc w/MTX- nausea/alopecia: 👉female sex 👉EtOH use 👉higher disease activity 👉belief that the med will cause it (older age assc w/⬇️risk of nausea) https://t.co/XDKFhvN0V1 @rheumnow

• Baseline Factors Associated with the Development of Nausea and Alopecia over On…

#ACR21 Ab#1444 @AhmadSherbini. Factors ass w/ nausea & alopecia in MTX ⭐️Nausea & alopecia: ♀️, 🥃, activity score are risk factors ▶️EtOH highlights importance of folic acid in these pts! @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/lxB2z2lXtu

• https://bit.ly/3qk9MB2

Love-hate relationship with #methotrexate. Side effects are common ex nausea/GI in 1/3 and alopecia in women. ?if you ask do you get more AES. Tough to treat especially SEs are early. ?Coach pt to help w persistence abst1444# @RheumNow #ACR21 https://t.co/NDQDVz8lk2

Abst1344 #ACR21 @RheumNow observational study of pts w/PsA treated w/b&tsDMARD:pts who achieve MDA (22.8% of pts at 6 mo) more likely to maintain the initiated bDMARD or tsDMARD Rx & less likely to switch from the initiated bDMARD/tsDMARD https://t.co/egFDHV3eQs